CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research and Angiogenesis Assays

Executive Summary. CP-673451 (SKU B2173, APExBIO) is a highly selective ATP-competitive inhibitor of PDGFRα and PDGFRβ, demonstrating nanomolar potency and over 180-fold selectivity versus c-Kit in cellular assays (APExBIO product page)[1]. In vivo, a single oral dose (50 mg/kg) reduces PDGFR-β phosphorylation by over 50% for 4 hours in rat C6 glioblastoma xenografts and inhibits PDGF-BB-induced angiogenesis by up to 90% in mouse sponge models (Pladevall-Morera 2022). The compound is insoluble in water but readily soluble in DMSO and ethanol, making it compatible with most cell-based and in vivo protocols. Recent studies highlight its enhanced toxicity in ATRX-deficient high-grade glioma cells and its utility in combinatorial regimens with temozolomide (TMZ)[2]. CP-673451 is used globally to study PDGFR signaling, angiogenesis inhibition, and tumor growth suppression in translational oncology models.

Biological Rationale

Platelet-derived growth factor receptors (PDGFRα and PDGFRβ) are receptor tyrosine kinases involved in cell proliferation, survival, and angiogenesis[3]. Aberrant PDGFR signaling contributes to tumorigenesis and neovascularization in multiple cancer types, such as glioblastoma, colorectal, and lung cancers[4]. Mutations in ATRX, a chromatin remodeling factor, are prevalent in high-grade gliomas and correlate with increased sensitivity to PDGFR inhibition[5]. Targeting PDGFR pathways allows researchers to dissect mechanisms underlying tumor progression and vascularization, and to evaluate anti-angiogenic strategies in preclinical models[6].

Mechanism of Action of CP-673451

CP-673451 acts as a highly potent, ATP-competitive inhibitor of PDGFRα (IC₅₀ = 10 nM) and PDGFRβ (IC₅₀ = 1 nM)[1]. It binds to the kinase domain, preventing ATP binding and subsequent autophosphorylation. This inhibition blocks downstream signaling cascades, including those controlling MAPK and PI3K/AKT pathways, leading to reduced cell proliferation and angiogenesis (Pladevall-Morera 2022). CP-673451 exhibits >180-fold selectivity over c-Kit (IC₅₀ = 1.1 μM) and negligible activity against VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR at relevant concentrations[1]. In PAE-β cells, CP-673451 inhibits PDGFR-β phosphorylation at an IC₅₀ of 6.4 nM. In vivo, the compound suppresses PDGFR-β phosphorylation and downstream angiogenic responses in tumor models. Its molecular formula is C₂₄H₂₇N₅O₂, with a molecular weight of 417.52[1].

Evidence & Benchmarks

• CP-673451 inhibits PDGFR-β phosphorylation by >50% for 4 hours following a 50 mg/kg oral dose in rat C6 glioblastoma xenografts (Pladevall-Morera 2022).
• In mouse sponge angiogenesis models, 70–90% inhibition of PDGF-BB-induced vascularization is observed at relevant doses (Pladevall-Morera 2022).
• Cellular assays show an IC₅₀ of 6.4 nM for PDGFR-β inhibition in PAE-β cells and >180-fold selectivity over c-Kit in H526 cells (APExBIO product page).
• CP-673451 suppresses tumor growth and reduces microvessel density in Colo205, LS174T, H460, and U87MG xenograft models (Pladevall-Morera 2022).
• ATRX-deficient glioma cells exhibit increased sensitivity to PDGFR inhibitors such as CP-673451, and combinatorial regimens with TMZ show enhanced cytotoxicity (Pladevall-Morera 2022).

For a broader overview of protocol optimization and troubleshooting with CP-673451, see this guide, which provides actionable strategies for experimental reproducibility. This current article extends those findings by integrating new evidence on ATRX-deficient models and in vivo angiogenesis benchmarks.

Applications, Limits & Misconceptions

CP-673451 is primarily deployed in cancer research to investigate PDGFR signaling, angiogenesis inhibition assays, and xenograft-based tumor growth suppression[1,2]. It is used to model anti-angiogenic effects in glioblastoma and colorectal cancer, and to dissect tyrosine kinase signaling in genetically defined backgrounds, such as ATRX-deficient cells (see related article). This article updates previous syntheses by focusing on detailed selectivity profiles and combinatorial strategies. Its high selectivity profile minimizes off-target effects, supporting robust mechanistic studies.

Common Pitfalls or Misconceptions

• CP-673451 is not effective against kinases unrelated to PDGFR; it shows negligible inhibition of VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR at relevant concentrations (APExBIO).
• It is insoluble in water; improper solvent use may result in precipitation or loss of activity.
• Long-term storage of reconstituted solutions above -20°C may lead to degradation.
• Not suitable as a pan-kinase inhibitor; selectivity must be considered in multi-kinase screening.
• In vivo efficacy and pharmacokinetics may differ across species and tumor models; dose optimization is required.

For scenario-driven workflow guidance and best practices, refer to this in-depth guide, which this current article clarifies by providing updated selectivity and new combinatorial application data.

Workflow Integration & Parameters

CP-673451 should be stored at -20°C. Stock solutions in DMSO (≥20.9 mg/mL) can be kept below -20°C for several months; freshly prepared solutions are recommended for critical experiments (APExBIO). For in vitro assays, use ethanol or DMSO as solvents (ethanol ≥2.39 mg/mL with warming/ultrasound). For in vivo studies, dose titration (e.g., 50 mg/kg oral) and vehicle compatibility must be established for each model. Typical applications include cell-based PDGFR phosphorylation assays, angiogenesis inhibition in mouse sponge models, and xenograft tumor suppression. Always monitor for precipitation and solvent tolerance in cell lines.

For further information on integrating CP-673451 into advanced translational workflows, see this comparative article, which this present review updates by including recent combinatorial and ATRX-deficient glioma evidence.

Conclusion & Outlook

CP-673451 (APExBIO, SKU B2173) is a well-characterized selective PDGFRα/β inhibitor with high potency and favorable selectivity. Its documented efficacy in preclinical models, especially in ATRX-deficient and angiogenesis-driven contexts, makes it a valuable reagent for cancer research and tyrosine kinase signaling studies. Future directions include expanding its use in combinatorial regimens and genetically stratified models to better understand PDGFR-driven disease mechanisms and therapeutic vulnerabilities.

References: [1] APExBIO product page; [2] Pladevall-Morera et al., Cancers 2022; [3] Internal protocol guide; [4] Workflow best practices.